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Abstract 
 In these studies, three different problems are looked at: the need for new 
compounds to treat infections caused by the Trichomonas vaginalis parasite, the 
development of methodology to induce production of new metabolites, and the 
development of methods to screen for compounds that protect or repair damage caused 
by traumatic injury. 
 In the first set of studies, the extraction, isolation, and elucidation of compounds 
from three different fungi was done. Dinapinones AB1/2, dinapinone A2, microsphaerin 
D, and a xanthoquinodin were found to show activity against the T. vaginalis parasite. 
The compounds were characterized using a combination of 1D and 2D NMR, mass 
spectrometry, infrared spectroscopy, and polarimetry. In the second set of studies, 
methodology was developed to try to induce production of new metabolites in fungi. 
Protocols to use new instrumentation capable of vaporizing microbial volatile oils over 
fungi were developed. Experiments to quantify the amounts of oil being delivered to 
fungal flasks were done as well. In the last study, a new assay to screen fungal extracts 
for activities in repairing or preventing damage from a traumatic injury was developed. 
In the development, multiple variables including, organism used, the pressure the 
cannon was fired at, and the distance the cannon was from the target were determined as 
part of the protocol for the assay. Initial results using pure compounds and fungal 
extracts were obtained and analyzed as well.
1 
Chapter 1  
Introduction 
 
1.1 Overview of Natural Products 
1.1.1 What are Natural Products 
Throughout history, people have utilized different biological sources for 
applications in medicine, weaponry, and cosmetics among others. The earliest 
discoveries in natural products were made through observations of organisms 
interacting with their environments. These observations helped mankind’s earliest 
ancestors determine that certain plants could be used to reduce pain, while other plants 
could be used for other purposes such as disinfecting wounds or healing infections 
without the use of sophisticated scientific techniques.
1
 Through the better understanding 
of these plants, the basis for many herbal and traditional medicines was developed.  
Within plants like the ones mentioned earlier, as well as other organisms, small 
compounds known as natural products can be found. Natural products play a wide range 
of roles in nature, and can be exploited by scientists for uses in medicine.  
New scientific techniques and technologies have benefited the field of natural 
products by streamlining the discovery of new compounds. Bioassay guided 
fractionation is typically used for the discovery of natural products and contains four 
main steps. First, a large number of extracts from different biological sources are tested 
in available assays. Common assays screen for toxicity towards cancers, parasites, and 
bacterial infections, but may also measure other activities of interest as well. The 
biological source of the active samples is then gathered in larger quantities for a large 
2 
scale extraction. The extract is separated orthogonally by vacuum liquid 
chromatography (VLC) or high performance liquid chromatography (HPLC). Assay 
results guide the separations until active compounds are isolated. These isolated 
compounds are analyzed with instruments like mass spectrometers (MS) for molecular 
weights and formulas, infrared spectroscopy (IR) for functional groups, and nuclear 
magnetic resonance (NMR) to construct the structure of the natural product using 1 and 
2D experiments as necessary.  
Unfortunately, since the 1980s, there has been a decline in natural products 
discovery due to the discovery process being costly, as well as having a large portion of 
active primary metabolites discovered.
2
 Secondary metabolites, which are often 
produced in miniscule amounts, are beginning to be explored more as the quality and 
capabilities of analytical instrumentation continues to improve. New advancements in 
research technology also allow for better understanding of drug targets, faster 
dereplication of known compounds, and more efficient high-throughput screenings of 
natural products in more specific assays.
3
 Overall, improvements in instrumentation 
streamlines the discovery process by saving time and money while increasing the 
confidence of the proposed structures for active compounds.  With continual 
improvements in technologies and instrumentation, the decline in natural products 
research is slowly being reversed.
3 
 
3 
 
1.1.2 Applications of Natural Products 
1.1.2.1 Applications as Drugs 
 Natural products play roles as treatments for a wide range of diseases and 
disorders; there are examples of compounds that have been discovered that treat both 
gram-positive and negative bacterial infections, as well as drug resistant infections, and 
Trichomonas vaginalis infections. Compounds have also been discovered that work as 
pain relievers as well as immunosuppressants. One well known pain reliever is 
morphine (1), a benzylisoquinoline alkaloid, of the opiate type. Morphine is mainly 
isolated from the poppy straw of the opium poppy and is highly addictive. Cyclosporin 
A (2) is an example of an immunosuppressant drug on the market used to prevent 
rejection after organ transplant surgeries. Cyclosporin A is a cyclic nonribosomal 
peptide consisting of 11 amino acids, isolated from the Tolypocladium inflatum fungus.
4
 
The drug has shown low toxicity levels in organ transplant patients helping them to 
improve their quality of life significantly.
5
 Phainanoid F (3) is a recently discovered 
highly modified triterpenoid from the Chinese shrub, Phyllanthus hainanensis that has 
shown promising immunosuppressive activities.
6
 Phainanoid F shows good potential as 
a drug candidate due to it being 7 and 221 times more active than cyclosporin A against 
proliferation of  both T and B lymphocytes respectively.
6
 These examples highlight the 
important utility of several natural products to the medical field. 
4 
Figure 1. 1 Natural product pain reliever 
 
 
Figure 1. 2 Natural product immunosuppressive compounds 
 
 
 
5 
1.1.2.2 Applications of Medicinal Chemistry in Natural Products  
There are many cases where some discovered natural product compounds show 
promise through activity, but other properties hinder them as a drug candidate. Common 
properties include poor solubility, therapeutic index (the ratio of LD50 to ED50), 
absorption, bioavailability, and non-ideal protein binding.
7
 Therefore, analogues of the 
natural compounds, where different functional groups can be changed on a scaffold, are 
synthesized by medicinal chemists to improve the drug-like qualities of a candidate. 
When multiple analogues and their activities are compared, it is called a structure 
activity relationship (SAR). The ultimate goal is to find a derivative of the original drug 
candidate that improves its effectiveness as a drug. Alternatively, computational studies 
can be used to predict structures that would bind better with proteins. A third option is 
to synthesize the drug candidate as a prodrug, where after administration, the human 
body metabolizes the compound into the pharmacologically active drug.
7
 One example 
of a commonly used prodrug is aspirin. With aspirin, acetylsalicylic acid (4) is 
converted to salicylate (5) in the stomach.
8
 The salicylate is responsible for the majority 
of the analgesic and anti-inflammatory effects of aspirin.
8
 Salicylic acid itself is a 
natural product found in willow bark, which has been used medicinally for centuries to 
treat aches, pains, and to reduce fevers.
9
 There are multiple other prodrugs available on 
the market currently, with ones like Prilosec, Tamiflu, and Plavix being blockbusters for 
the companies that patented them. Tamiflu is also based off of a natural product. 
6 
Figure 1. 3A prodrug pain reliever and the metabolized active compound 
 
 
1.1.2.3 Discovery of Taxol 
Taxol (6) is an anticancer drug, and has been used to treat metastatic carcinoma 
of the ovary, metastatic breast cancer, and non-small cell lung cancer.
10
 Applications for 
the use of the drug outside of cancer treatment are still being studied and expanded.
10
 
Figure 1. 4 A natural product anti-cancer therapeutic compound 
 
Taxol was originally isolated from the wood bark of the yew tree, Camptotheca 
acuminata, and is one of the most prominent examples of a natural product that has 
become a leading anticancer drug.
11
 Taxol was found to work through a unique 
mechanism, where the compound would bind to tubulin protein. Tubulin forms 
microtubules, proteins of cellular cytoskeletons, which are integral to cell division. The 
7 
binding to tubulin prevents cancer cells from dividing and therefore impedes cancer 
growth.
11
 Taxol has been found in the bark of several other tree species as well, but  it is 
found in low concentrations in even the most productive source, Taxus brevifolia.
10
 In 
order to acquire 1 kg of taxol,10,000  kg of Taxus bark, or approximately 300 yew trees, 
would be required.
10
 Due to its success as an anti-cancer drug, there is a high demand 
for taxol, which in turn places a high level of pressure on the trees that produce the 
compound. 
Several different approaches have been taken in order to overcome the low yield 
of taxol from Taxus bark, including synthesis, discovery of alternate sources, and 
bioengeneering. Synthesis has been the most studied method for obtaining more taxol, 
in fact Holton, Nicolaou, and Danishefsky, have all developed independent total 
synthesis routes to obtain the compound. Unfortunately, none of the developed total 
syntheses can be commercialized since the methods require over twenty steps with a 
low yield.
12
 An alternative approach began development in 1993, when it was 
discovered that there were taxol-producing endophytic fungi. The different fungi were 
found to be capable of producing between 24 ng and 70 μg of taxol per liter of culture. 
Although the amount of the drug obtained is low from this method, the fungi's rapid 
growth would help reduce the strain on the yew tree forests caused by the demand for 
taxol.
12
 The last approach that has been looked at in order to obtain taxol is through 
bioengineering. In this method, the genes required to biosynthesize taxol can be 
incorporated into other organisms in a similar way to how E. coli have been 
bioengineered to produce insulin, a hormone normally produced by the pancreas.
13
 The 
majority of the biosynthetic pathway has been elucidated, but the pathway is still not 
8 
completely understood. With the advancement of this area, fast-growing organisms like 
E. coli can be engineered to over-express or suppress genes in order to maximize the 
production of taxol.
12
 Bioengineering shows good potential to produce greater 
quantities of the drug, but at this time only several intermediates of taxol have been 
obtained.
12
 Other natural products, like taxol, often face similar problems of low yields 
of material, but through troubleshooting methods like the ones shown here, it is possible 
to overcome these obstacles. Despite, the problems faced in producing taxol, in the past 
decades, natural products have continued to supply new sources for drugs and 
therapeutics.  
 
1.2 Drug Resistance and Natural Products 
 As a population, mankind has recently arrived at a new dark age; cases have 
begun to show up of resistance to drugs of last resort. Until recently, colistin (7), one of 
the drugs of last resort used to treat multi-drug resistant infections, was known to not 
have any drug resistances.
14
 In 2015, reports were made that E. coli. and Klebsiella 
pneumoniae had developed resistances to colistin, in the first cases of plasmid-mediated 
resistance to a drug of last resort.
14-15
 This type of resistance occurs when a bacteria 
accumulates mutations on a plasmid that give it resistance and then passes the mutation 
on to other bacteria through a horizontal gene transfer.
15
 The problem is exacerbated by 
the fact that research has not been able to develop new drugs to keep up with the rate 
that bacteria have been developing resistance to antibiotics.  
9 
Figure 1. 5 One of the drugs of last resort 
 
Natural products can help create solutions to the drug-resistance problem by 
providing new drug leads through the investigation of compounds from a variety of 
biological sources. One such lead that is currently in development, is a natural product 
discovered from the bacteria Eleftheria terrae, a previously unculturable bacteria that 
produces teixobactin (8).
16
 The compound has been found to have great minimal 
inhibitory concentration (MIC) values in the low μg/mL range for a range of pathogenic 
organisms including Methicillin-resistant Staphylococcus aureus (MRSA) (0.078-0.31 
μg/mL), Enterococcus (0.31-0.63 μg/mL), Streptococcus (0.02-0.15 μg/mL), and M. 
tuberculosis (0.125-0.31 μg/mL) which are known to have multiple drug resistances.16 
Teixobactin currently does not have any drug resistance and is unlikely to develop 
resistance rapidly based on studies done on the mechanism of action. These studies 
show that the compound appears to have a low susceptibility for resistances to 
develop.
16
 Compounds like teixobactin provide hope that there are other natural 
products that can help counter the resistances that are being developed to current 
available drugs.  
10 
Figure 1. 6 A new natural product antibiotic drug candidate 
 
 
1.3 Utility of Fungi in Natural Products 
 Microbes are an effective source for the production of natural product drugs. 
Over 23,000 active compounds have been discovered; of those compounds fungi 
produce the most with 42% of the compounds, while filamentous bacteria produce 32%, 
and other types of microbes combine to produce the remaining 26%.
17
 Fungi provide a 
promising source for new compounds for several reasons. Currently only a small 
portion of the vast diversity of fungi has been explored; in fact, there are many genera 
and species that have yet to be discovered. New molecular methods and studies of 
environmental DNA samples estimate that between 3.5 and 5.1 million different species 
of fungi exist on this planet.
18
 Despite, the immense amount of species, only around 
70,000 have been described at this time.
18
 With millions of fungal species yet to be 
discovered, there is potential for a wide range of new natural products. 
One of the most famous fungal natural products is penicillin (9), which was 
discovered in 1928 from the Penicillium notatum fungus.
19
 Penicillin was discovered 
11 
when Alexander Fleming found an inhibitory zone on a Staphylococcus plate coming 
from a Penicillium contamination.
19
 The discovery of penicillin has helped save 
millions of lives over the course of the years. Penicillin has also furthered the medical 
field by allowing for the isolation of new bacteria, further development of new types of 
penicillin derivatives, and has provided treatments for a large spectrum of bacterial 
infections, including the hard to treat gram-negative bacterial infections. Unfortunately, 
overuse and misuse of the penicillins has created strains of bacteria that are now 
resistant to this drug class, creating a further need for new antibiotics.  
Figure 1. 7 A fungal anti-bacterial natural product 
 
In addition to being a source of diversity and useful chemistry, fungi are also 
easy to culture in a laboratory setting. Reisolation of compounds can be a particularly 
difficult challenge with other types of organisms, like plants and marine sources, which 
may not be found producing the same materials if they are collected a second time, even 
if the samples are collected from the same place as the first time. Nutrients available at 
one time may change over periods and prevent certain metabolites from forming in 
those organisms. Therefore, consistency of culture is particularly important when 
obtaining a compound of interest. For fungi, inoculation on media requires only a single 
spore that is typically hardy and grows rapidly compared to plants and sponges.  
12 
Fungi display a wide range of biosynthetic pathways that can lead to new 
metabolites, and therefore new medicinal compounds. Fungi have many genes that lie 
dormant and unused, but can be activated through epigenetic modifications. Epigenetic 
modifications modulate genes depending on environmental triggers including 
nourishment of the fungus during growth as well as chemical signals.
20
 By taking 
advantage of gene modulation in the fungi, opportunities to produce a wide range of 
metabolites are opened up.
21
 Epigenetic modifications can help lead to the discovery of 
new derivatives of known compounds as well as new scaffolds for drug candidates. 
 
1.5 Project Objectives 
The following studies in fungal natural products will be presented in three parts: 
applications in treating Trichomonas vaginalis infections using fungal metabolites, the 
induction of new secondary metabolites in fungi through the introduction of volatile oils 
commonly found in soil through a vapor vehicle, and the development of a traumatic 
injury assay to test fungal extracts and pure compounds. In the Trichomonas studies, the 
focus will be on the isolation, identification of active structures, and bioactivity testing. 
For the studies in induction of new metabolites in fungi; the development of the 
methodology, the design of the instrumentation, as well as the comparison of the 
compounds produced will be presented. Finally, with the traumatic injury assay; the 
focus will be the determination of organisms used, development of the methodology, 
design of the equipment, troubleshooting of variables, initial compound and extract 
testing, and future directions for the assay. 
  
13 
Chapter 2 
Fungal Metabolites Active Against Trichomonas vaginalis 
 
2.1 Introduction 
 Trichomonas vaginalis is an anaerobic, flagellated protozoan parasite that causes 
the infectious disease trichomoniasis.
22
 This disease is one of the most prevalent non-
viral sexually transmitted infections in the United States, surpassing even chlamydia 
and gonorrhea.
23
 Little attention is paid to trichomoniasis even though it is estimated 
that 5 million new cases appear annually.
23
 This is partially due to the fact that T. 
vaginalis infections can be asymptomatic or have mild symptoms leading to the 
infection being undiagnosed.
24
 When trichomoniasis does show symptoms, it is most 
frequently seen in women as pruritis, vaginitis, vulvitis, dysuria, dyspareunia, as well as 
occasionally colpitis macularis (strawberry cervix).
24
 Occasionally, complications do 
arise as a result of T. vaginitis infections which can include inflammatory conditions, 
cervical erosion, cervical cancer, as well as infertility.
24
 Trichomoniasis is not the only 
problem that is caused by T. vaginalis. There has recently been increasing amounts of 
data that has linked the parasite to human immunodeficiency virus (HIV) transmission, 
as well as perinatal morbidity.
25
 
 In order to treat infections of T. vaginalis, doctors usually prescribe a 
nitroimidazole (Figure 2.1) such as metronidazole (1). The drug has been found to 
display activity against other anaerobic protozoa and bacteria in addition to its role in 
treating trichomoniasis.
26
 The other nitroimidazole drug that is commonly used to 
combat T. vaginalis is tinidazole (2), which has similar safety worries and effectiveness 
14 
as metronidazole but is more expensive and is also used in metronidazole-resistant 
trichomoniasis.
27
 There are few alternative treatments as effective and safe as the 
nitroimidzoles against trichomniasis, and slowly T. vaginalis parasites are developing 
resistance to metronidazole.
25
 With the lack of any other approved drugs to treat 
trichomoniasis besides the nitroimidazoles, there is a significant need for new 
compounds that show good efficacy against T. vaginalis as well as low toxicity to 
humans. The projects presented in this chapter, display results for compounds isolated 
from three different fungi showing the activity in killing the T. vaginalis parasite. For 
each of the projects, the isolation, elucidation, and activities of the active metabolites 
are discussed. The projects are the Wailua PDA-3 Contaminant, Tracy MEA-2, and 
Boars Tusk PFA-1 fungi. 
 
Figure 2. 1 Structure of Compounds 1, 2 
 
2.2 Wailua PDA-3 Contaminant 
Table 2. 1 Key for identification of compounds from the Wailua PDA-3 Contaminant 
fungus 
Compound # Notebook Code Compound Name 
3 107KB26C Dinapinone AB1/2 
4 107KB26B Dinapinone A1/A2 
5 107KB42B Dinapinone A2 
15 
2.2.1 Isolation of Dinapinones from Trichoderma citrinoviride 
 Six bags of fungi grown on Cheerios
®
 were used for the extraction of these 
compounds. The compounds were extracted by blending the fungi and Cheerios
®
  in 
ethyl acetate and allowing the mixture to sit overnight before evaporating the solvent to 
get a crude extract. Fractionation of the extract was done using vacuum liquid 
chromatography with silica gel before running bioactive fractions on HP20SS resin. 
Afterwards a Sephadex size exclusion column was run to separate compounds before 
further purification was done using Preparatory and Semi-Preparatory High 
Performance Liquid Chromatography (HPLC). 
 
2.2.2 Dereplication of compounds 3, 4, and 5 
 Using a combination of mass spectrometry, as well as 
1
H and 
13
C nuclear 
magnetic resonance (NMR) experiments, a range for the number of protons and carbons 
was determined and searched for in the online database, Dictionary of Natural 
Products
©
 database. Mass spectrometry showed that compound 3, shown in Figure 2.2, 
had a m/z of 791 [M+H]
+
 while compound 4, shown in Figure 2.2, had a m/z of 835 
[M+H]
+
. The 2-D experiments NMR experiments, heteronuclear single quantum 
coherence (HSQC)  and heteronuclear multiple bond correlation (HMBC), were  run for 
compound 3 and resulted in partial structures that were compared to a list of compounds 
found on the Dictionary of Natural Products. Compound 3 was found to be dinapinone 
AB1/2 (6.9 mg) with a molecular formula of C44H54O13. The absolute configuration was 
not determined, since the atropisomers were not separated out, and optical rotation was 
not done. Compound 4 had an almost identical UV profile and was believed to be a 
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derivative of compound 3. A search narrowed by molecular weight and suspected 
proton range on the Dictionary of Natural Products resulted in a dinapinone derivative 
suspected to be  compound 4. After comparing 
1
H NMR data with literature values, 
compound 4 was determined to be either dinapinone A1 or A2 (21.5 mg) with a 
molecular formula of C46H59O14.
28-29
 Compound 4 was then separated further to produce 
a pure compound, 5, shown in Figure 2.4, with an optical rotation of +200°, matching 
that of dinapinone A2. 
Figure 2. 2 Structures of Compounds 3 and 4 
 
 
2.2.3 Dinapinone AB1/2 and Dinapinone A1/2 
 Dinapinone A1 and A2 (4) were originally reported as isolated from Penicillium 
pinophilum
29
 while Dinapinone AB1 and AB2 (3) were originally reported to be 
isolated from Talaromyces pinophilus.
28
 The compound similarity between the two 
fungi can be explained by the Talaromyces being a teleomorphic state of Penicillium.
30
 
These  dinapinone compounds produced by the Penicillium fungus and its teleomorph  
are part of a series of new dihydronaptho-pyranone-containing compounds.
29
 Both sets 
of isolated dinapinones, A1/A2 and AB1/AB2 are atropisomers, with 4 being a dimer 
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made up of monopinone A, and 3 being made up of a combination of the monopinone A 
and B monomers, shown in Figure 2.3. 
Figure 2. 3 Monomer units that make up 3 and 4 
 
Both sets of atropisomers were originally found to be potent inhibitors of 
triacylglycerol synthesis in mammalian cells.
28-29
 In the current investigation, 3 and 4 
were originally being isolated following weak activity in MIA PaCa cells, but were later 
found to have more potent activity against T. vaginalis (assay results are shown in 
Appendices A10, A12, and A14). Further separation was performed on compound 4 
using a biphenyl column to separate the atropisomers. Specific rotation studies were 
done on the isolated compounds, which were determined to be [α]D
26
 of +200° and 
+80°. The rotation of +200° for the purified compound was similar to the literature 
value of +243.6° and was determined to be dinapinone A2 (5). The +80° rotation was 
not similar to the literature value for dinapinone A1, which should have been -190.1°, 
and it was not possible for a high resolution NMR spectrum to be taken. It appears that 
the second compound may have degraded, so the identity of the second compound 
remains unknown. 
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Figure 2. 4 Structure of Compound 5 
 
 
2.2.4 Summary 
 Two sets of atropisomers were isolated from Trichoderma citrinoviride. 
Atropisomer mixture 4 was separated using a biphenyl column to isolate the 
atropisomers. A specific rotation experiment determined that 5 was dinapinone A2. The 
structure of the other isolated compound was not able to be determined. Both sets of 
atropisomers were found to be dinapinones with the AB1/AB2 (3) isomers being 
isolated along with dinapinone A2 (5). The isolated compounds were submitted for 
biological assays where it was found that 3 had a therapeutic index (TI) of 
approximately 5 while 5 had a TI of greater than 5. An unidentified compound, fraction 
42C, showed stronger activity with a TI of 12.5. Further work was not done because it 
was discovered that the dinapinones lost activity in anaerobic conditions. For assay 
results see Appendices A.10, A.12, and A.14. 
 
2.2.5 Experimental Methods 
2.2.5.1 Instrumentation 
Optical rotation data was determined on a Rudolph Research AUTOPOL III 
automatic polarimeter. NMR data was collected on a Varian 400 MHz NMR 
spectrometer. Accurate mass data was collected on an Agilent 6538 HRESI QTOF MS 
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coupled to an Agilent 1290 HPLC. LCESIMS data was obtained on a Shimadzu LC-MS 
2020 system (ESI quadrupole) coupled to a photodiode array detector, with a 
Phenomenex Kintex column (2.6 μm C18 column, 100 Å, 75 × 3.0 mm). The 
preparative HPLC system utilized SCL-10A VP pumps and system controller with a 
Gemini 5 μm C18 column (110 Å, 250 × 21.2 mm, 10 mL/min), and the analytical and 
semi-preparative HPLC system utilized Waters 1525 binary pumps with Waters 2998 
photodiode array detectors and Gemini 5 μm C18 columns (110 Å, 250 × 4.6 mm, 1 
mL/min and 110 Å, 250 × 10 mm, 4 mL/min) as well as Kinetex 5 μm Biphenyl 
columns (110 Å, 250 × 4.6 mm, 1mL/min and 100 Å, 250 × 10 mm, 4 mL/min .  
 
2.2.5.2 Extraction and isolation of compounds 
. The fractions used to isolate these compounds were generated from the 
extraction of six bags of Trichoderma citrinoviride fungus in ethyl acetate. The extract 
was fractionated over silica gel and eluted with hexane−CH2Cl2−MeOH (hexane, 50:50 
hexane− CH2Cl2, CH2Cl2, 90:10 CH2Cl2−MeOH, MeOH). Fraction 15D was applied to 
an HP20ss column, and eluted with a MeOH−H2O stepwise gradient (20%, 40%, 60%, 
80%, 100% MeOH) with a 50:50 MeOH-CH2Cl2 wash. The fifth fraction (100% 
MeOH) was further separated over Sephadex LH20 (eluted with CH2Cl2) to yield eight 
subfractions. Subfraction 3 was separated by C18 preparative HPLC (gradient elution 
with MeOH−H2O from 60:40 to 100% organic phase over 30 min) followed by C18 
semi-preparative HPLC (isocratic MeCN− H2O, 69:31) to obtain 3 (6.9 mg), and 4 
(21.5 mg). Subfraction 2 was further separated using Biphenyl semi-preparative HPLC 
20 
(isocratic MeCN-H2O-HCOOH 0.1%, 55:45) to obtain 5 (2.1 mg). The full separation 
scheme is shown in Figure 2.5.  
Figure 2. 5 Separation flow chart for Compounds 3, 4, and 5 
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2.2.6 Experimental Data 
 Dinapinone AB1/2 (3): pale brown powder (6.9 mg), 
1
H and 
13
C NMR data: see 
Appendix A.1 for spectra and A.4 for table of values, LCESIMS m/z 789.35 ([M-H]
-
, 
calculated for C44H54O13 789.3492) 
 Dinapinone A2 (5): yellow powder (21.5 mg), [α]D
26
 +200 (c 0.1, methanol), 
1
H 
and 
13
C NMR data: see Appendix A.3 for spectrum and A.4 for table of values, 
LCESIMS m/z 835.50 (M+H)
+
, formula C46H59O14 835.9540, see Appendix A.2 for 
HRESIMS) 
 
 2.3 Tracy MEA-2 
Table 2. 2 Key for identification of compounds from the Tracy MEA-2 fungus 
Compound # Notebook Code Compound Name 
6 107KB64F & 77E Xanthoquinodin 
 
2.3.1 Isolation of a xanthoquinodin from Humicola grisea var. grisea 
Three bags of fungi were grown on Cheerios and used for the extraction of the 
bioactive compound. The compound was extracted by blending the fungi and cheerios 
in ethyl acetate and allowing the mixture to sit overnight before evaporating the solvent 
to make the crude extract. Fractionation of the extract was done using vacuum liquid 
chromatography with silica resin before running bioactive fractions on HP20SS resin. 
Afterwards samples were further isolated and purified using Preparatory and Semi-
Preparatory HPLC chromatography. 
22 
 
2.3.2 Dereplication of compound 6  
Liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-
MS) data and the University of Oklahoma Natural Products Discovery Group (NPDG) 
database of discovered compounds were used to determine the structure of 6. After 
running an HP20SS column on the active sample, the m/z of one of the peaks found in 
the LCESIMS PDA chromatogram matched with a class of compounds found in the 
NPDG database. Xanthoquinodins, shown in Figure 2.7, with a m/z of 573.25 [M+H]
+
,
 
showed up as a match in retention time and UV. After isolating the active compound, a 
1
H NMR spectra was taken of the isolated compound and was compared to the literature 
values for the xanthoquinodins. The shifts of the proton peaks matched and compound 6 
was determined to be one of the xanthoquinodins. While optical rotation of the isolated 
compound was not taken due to the degradation , the assay data, shown in Figure 2.6, is 
most similar to xanthoquinodin A1 or B2 
23 
Figure 2. 6 Assay results for the isolated compound (64F) compared to all of the 
identified xanthoquinodins 
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Figure 2. 7 Structure of Compound 6 
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2.3.3 Xanthoquinodins  
 Xanthoquinodins are a heterodimer structure consisting of octaketide-derived 
xanthone and anthraquinone moieties (Figure 2.8) that are linked in a unique way.
31
 
Xanthoquinodins were first reported in the literature as being part of a series of fungal 
metabolites isolated from Humicola sp. FO-888.
31
 The xanthoquinodins have been 
reported to exhibit anticoccidal activity in an in vitro assay using the Eimeria tenella 
parasite in BHK-21 host cells.
31
 6 has now been found exhibit activity against T. 
vaginalis in an in vitro assay as well. 
Figure 2. 8 Units that make up xanthoquinodins 
 
 
2.3.4 Summary 
One known compound was isolated from Humicola grisea var. grisea, 
compound 6, was isolated using a C18 semi-prep column. The compound was able to be 
dereplicated using a combination of 
1
H NMR and the NPDG database. The pure 
compound was submitted for biological assays where it was found that compound 6 had 
a TI of approximately 5, which was retained when retested in anaerobic conditions. For 
assay results see Appendices A.11, A.12, and A.14. Further work was not done on the 
compound. 
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2.3.5 Experimental Methods 
2.3.5.1 Instrumentation 
NMR data was collected on a Varian 400 MHz NMR spectrometer. LCESIMS 
data was obtained on a Shimadzu LC-MS 2020 system (ESI quadrupole) coupled to a 
photodiode array detector, with a Phenomenex Kintex column (2.6 μm C18 column, 
100 Å, 75 × 3.0 mm). The preparative HPLC system utilized SCL-10A VP pumps and 
system controller with a Gemini 5 μm C18 column (110 Å, 250 × 21.2 mm, 10 
mL/min), and the analytical and semi-preparative HPLC system utilized Waters 1525 
binary pumps with Waters 2998 photodiode array detectors and Gemini 5 μm C18 
columns (110 Å, 250 × 4.6 mm, 1 mL/min and 110 Å, 250 × 10 mm, 4 mL/min). 
 
2.3.5.2 Extraction and Isolation of Compounds 
 The fractions used to isolate these compounds were generated from the 
extraction of three bags of Humicola grisea var. grisea fungus in ethyl acetate. The 
extract was processed following a prefractionation protocol implemented for improved 
assay screening. The sample was fractionated over silica gel and eluted with 
hexane−CH2Cl2−MeOH (hexane, 50:50 hexane−CH2Cl2, CH2Cl2, 90:10 
CH2Cl2−MeOH, MeOH). Subfraction 3 was applied to an HP20ss column, and eluted 
with a MeOH−H2O stepwise gradient (30%, 50%, 70%, 90%, 100% MeOH) with a 
50:50 MeOH-CH2Cl2 wash. A portion of the fifth fraction (100% MeOH) was further 
separated by C18 preparative HPLC (gradient elution with MeOH−H2O from 80:20 to 
100% organic phase with 0.1% formic acid in the aqueous phase over 30 min) followed 
26 
by C18 semi-preparative HPLC (gradient elution with MeCN− H2O with 0.1% formic 
acid from 60:40 to 100% organic phase with 0.1% formic acid in the aqueous phase 
over 15 minutes) on subfraction 6 to obtain compound 6 (3.8 mg). The full separation 
scheme is shown in Figure 2.9. 
Figure 2. 9 Separation flow chart for Compound 6 
 
 
2.3.6 Experimental Data 
Xanthoquinodin (6): yellow powder (3.8 mg), 
1
H NMR data see Appendix A.5 
for spectrum and A.6 for table of values, LCESIMS m/z 573.30  ([M+H]
+
, calculated for 
C31H24O11 572.5157) 
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2.4 Boars Tusk PFA-1 
Table 2. 3 Key for identification of the compound from the Boars Tusk PFA-1 fungus 
Compound # Notebook Code Compound Name 
7 107KB30A Microsphaerin D 
 
2.4.1 Isolation of Microsphaerin D and Unidentified Compound from Uncultured 
Pleosporales clone 165 
Six bags of fungi grown on Cheerios were used for the extraction of these 
compounds. The compounds were extracted by blending the fungi and cheerios in ethyl 
acetate and allowing the mixture to sit overnight before evaporating the solvent to 
obtain the crude extract. Fractionation of the extract was done using vacuum liquid 
chromatography with silica resin before running bioactive fractions on HP20SS resin. 
Afterwards, samples were further purified using preparatory and semi-preparatory 
HPLC chromatography. 
 
2.4.2 Dereplication of compounds 7 
 Using a combination of mass spectrometry, 
1
H and 
13
C NMR, a range for the 
number of protons and carbons was determined and searched for in the Dictionary of 
Natural Products. Mass spectrometry showed that Compound 7 had a m/z of 547.30 
[M+H]
+
. Using the HSQC and HMBC experiments run for compound 7, partial 
structures were pieced together and compared to a list of compounds on the Dictionary 
of Natural Products database. Compound 7 was found to be microsphaerin D (10.7 mg) 
as shown in Figure 2.10, with a molecular formula of C30H26O10.  
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2.4.3 Microsphaerin D  
 Microsphaerin D (7) is one of four  benzophenone dimers that were first isolated 
from two strains of the anamorphic fungus, Microsphaeropsis F2076 and F2078.
32
 
These fungi were found in lake sediment collected from Singapore. Compound 7 was 
originally found to display antibacterial activity against MRSA in the low micromolar 
range.
32
 7 has now been found to show activity against T. vaginalis in an in vitro assay 
as well. 
Figure 2. 10 Structures of Compound 7 
 
 
2.4.4 Summary 
Two compounds were isolated from the Uncultured Pleosporales clone 165 
fungus. Compound 7 was isolated using a C18 semi-preparatory column, and the 
unidentified compound was isolated along with a contaminant using a biphenyl semi-
preparatory column. Using both 1D and 2D NMR experiments it was possible to 
determine that 7 was microsphaerin D. The unidentified compound was isolated with an 
impurity, but due to low amount of material the impurity could not be removed. Both 
1D and 2D sets of NMR data were collected, but it was not possible to solve the 
structure of the compound. It appears that the unidentified compound has approximately 
29 
50 hydrogen and 31 carbons. Both compounds were submitted for biological assay and 
7 was found to have a TI of 0.3. The unidentified compound showed good activity but a 
TI value was not determined. For assay results see Appendices A.13 and A.14. 
 
2.4.5 Experimental Methods 
2.4.5.1 Instrumentation  
IR data were collected on a Shimadzu IR Affinity FTIR. NMR data was 
collected on Varian 400 and 500 MHz NMR spectrometers. Accurate mass data was 
collected on an Agilent 6538 HRESI QTOF MS coupled to an Agilent 1290 HPLC. 
LCESIMS data was obtained on a Shimadzu LC-MS 2020 system (ESI quadrupole) 
coupled to a photodiode array detector, with a Phenomenex Kintex column (2.6 μm C18 
column, 100 Å, 75 × 3.0 mm). The preparative HPLC system utilized SCL-10A VP 
pumps and system controller with a Gemini 5 μm C18 column (110 Å, 250 × 21.2 mm, 
10 mL/min), and the analytical and semi-preparative HPLC system utilized Waters 
1525 binary pumps with Waters 2998 photodiode array detectors and Gemini 5 μm C18 
columns (110 Å, 250 × 4.6 mm, 1 mL/min and 110 Å, 250 × 10 mm, 4 mL/min) as well 
as Kinetex 5 μm Biphenyl columns (110 Å, 250 × 4.6 mm, 1m mL/min and 100 Å, 250 
× 10 mm, 4mL/min.  
 
2.4.5.2 Extraction and isolation of compounds 
The fractions used to isolate these compounds were generated from the 
extraction of six bags of Pleosporales clone 165 fungus in ethyl acetate. The extract 
was processed following the prefractionation protocol. For compound 7, the extract was 
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fractionated over silica gel and eluted with hexane−CH2Cl2−MeOH (hexane, 50:50 
hexane−CH2Cl2, CH2Cl2, 90:10 CH2Cl2−MeOH, MeOH). Subfraction 3 was applied to 
an HP20ss column, and eluted with a MeOH−H2O stepwise gradient (30%, 50%, 70%, 
90%, 100% MeOH) with a 50:50 MeOH-CH2Cl2 wash. A portion of the fifth fraction 
(100% MeOH) was further separated by C18 preparative HPLC (gradient elution with 
MeOH−H2O from 90:10 to 100% organic phase with 0.1% formic acid in the aqueous 
phase over 30 min) followed by C18 semi-preparative HPLC (Isocratic MeCN− H2O 
with 0.1% formic acid, 53:47) on subfraction 3 to obtain compound 7 (10.7 mg). 
For the unidentified compound, subfraction 4 from the silica resin column was 
applied to an HP20ss column. The material on the HP20ss column was eluted with a 
MeOH−H2O stepwise gradient (30%, 50%, 70%, 90%, 100% MeOH) with a 50:50 
MeOH-CH2Cl2 wash. A portion of the sixth subfraction (50:50 MeOH-CH2Cl2 wash) 
was further separated by a second silica column using a hexane−ethyl 
acetate−MeOH−acetone gradient (hexane, 3:1 hexane−ethyl acetate, 1:3 hexane−ethyl 
acetate, ethyl acetate, MeOH, acetone wash) followed by C18 semi-preparative HPLC 
(isocratic MeCN− H2O with 0.1% formic acid, 72:28) on subfraction 5. This was then 
followed by biphenyl semi-preparative HPLC (isocratic, MeCN− H2O with 0.1% formic 
acid, 63:37) to obtain the unidentified compound in an impure state (2.3 mg). The full 
separation scheme is shown in Figure 2.11. 
31 
Figure 2. 11 Separation flow chart for Compound 7 
 
 
2.4.6 Experimental Data 
Microsphaerin D (7): yellow powder (10.7 mg), 
1
H, 
13
C, and 2D NMR data 
Appendix A.7 for spectra and Appendix A.8 for table of values, LCESIMS m/z 547.30  
([M+H]
+
, calculated for C30H26O10 546.5214) 
 
Unidentified Compound: yellow powder (2.3 mg, mostly pure compound), 
LCESIMS m/z 501, [M+H]
+
, formula not determined, see Appendix A.9 for spectra 
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Chapter 3 
Induction of New Secondary Metabolites Using Volatile Oils 
 
3.1 Introduction 
 In the past few decades, researchers have elucidated many primary metabolites 
from different organisms and as a result there has been a shift to exploration of 
secondary metabolites. This shift has resulted in increasing numbers of metabolites 
being discovered, making it more difficult to identify new natural products. As a result, 
there is a need to develop novel ways of inducing the production of new compounds in 
organisms.   
All organisms have an integrated network of enzyme-mediated and carefully 
regulated chemical reactions.
33
 Many of these metabolic pathways are involved in 
breaking down compounds so that they can be utilized as building blocks to synthesize 
specialized compounds used for energy, growth, and defense.
33
 Many of these 
compounds are produced in lower quantities than primary metabolites and are known as 
secondary metabolites. Due to their low abundance, leading to difficulties in isolation 
and elucidation, secondary metabolites have seen limited discovery at this point in time. 
By making modifications to the biosynthetic pathways used by organisms, many of the 
less abundant metabolites can be made easier to obtain, and new compounds may be 
produced as well. For example, in the Fusarium oxysporum fungus, two new derivatives 
of fusaric acid, a compound normally found in the fungus, were produced when 
suberohydroxamic acid (SBHA), a competitive histone deacetylase (HDAC) inhibitor, 
was added to the growth medium.
21
 Production of the two derivatives was not seen 
33 
without the addition of the SBHA.
21
 This example of the alteration of biosynthesis in 
the fungus  was accomplished through the employment of epigenetic modification. This 
modification resulted in changes in metabolic pathways being activated or deactivated, 
producing the new derivatives. 
Epigentic modification, like in the example before, occurs through the alteration 
of gene expression without affecting the DNA sequence of the organism.
34
 Genome 
sequencing has revealed many different biosynthetic gene clusters that can be used for 
the production of new natural products.
35
 There have even been cases where the 
modification of genes has resulted in the generation of structurally unique natural 
products. Two classes of compounds have been shown to work particularly well as 
epigenetic modifying agents, multiple histone deacetylase (HDAC) and DNA 
methyltransferase (DNMT) inhibiting compounds; although these two classes are not 
the only ones capable of epigenetic modification 
35-36
  
In this study, it was believed that new metabolites could be produced by 
vaporizing microbial volatile oils over different fungi. The interactions that fungi had 
with these volatile compounds was expected to produce epigenetic modification in the 
fungi, resulting in new natural products being produced. To prove this concept, new 
methodology was developed for the use of a vaporizing instrument, oil quantification 
studies were performed, and initial studies with fungi were recorded.  
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3.2 Fungal Smoker 
3.2.1 Instrumentation 
 For the studies in this project, an instrument was developed which can activate 
four e-cigarette cartomizers (dual coil, 1.5 mL, 510 thread type, 2.0 ohm) at the same 
time and then push the resulting vapors into fungus filled flasks. This instrument has 
been named the "Fungal Smoker". The Fungal Smoker uses an arduino board 
programmed to activate the Fungal Smoker at 3, 8, or 24 hour intervals. Upon 
activation, a current is run from the cartomizer housing on the top of the Fungal Smoker 
and through the heating coil inside the cartomizer, which vaporizes the propylene 
glycol, glycerine, and oil mixtures. At the same time, an aquarium pump is turned on, 
pumping air from an external air source through all four cartomizers in order to push the 
vapors into the fungus filled flasks. This method allows for a consistent application of 
volatile oils to the fungi at preset and regulated intervals. Figure 3.1 shows the external 
setup of the Fungal Smoker, as well as the setup of the experiment. 
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Figure 3. 1 Labeled diagram of the Fungal Smoker 
 
 
3.2.2 1-Octanol Quantification Studies 
 In this study, the amount of 1-octanol being delivered by the Fungal Smoker was 
quantified. This experiment was done in order to determine if the oil distribution 
between flasks was consistent. The study also allowed for the determination of the 
percent of 1-octanol retained in the flask from the amount of the oil initially vaporized. 
For this experiment, a 5 M concentration of 1-octanol in 1:1 propylene 
glycol:glycerine solution was prepared. The solution was then loaded into an e-cigarette 
cartomizer until the cartomizer was full. The mass of the full cartomizer was then 
obtained. At this point, the cartomizer was connected to the Fungal Smoker and two 1 
liter Erlenmeyer flasks using Tygon tubing and a plastic Y-splitter. The Fungal Smoker 
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was then turned on and activated for one cycle, after which the mass of the cartomizer 
was determined. This process was repeated two more times. 
The 1-octanol needed to be isolated in order to determine the mass delivered by 
the Fungal Smoker. To do this, the sides of the flasks were rinsed with hexanes and 
water before the solvents were poured into a separatory funnel. The octanol-containing 
hexanes layer was collected in a scintillation vial, and the hexanes were evaporated on a 
rotary evaporator. The remaining water in the separatory funnel was mixed with 
hexanes again. The hexanes layer was collected and dried  in the same scintillation vial 
before a drying agent was added to remove any remaining water. The dry 1-octanol was 
dissolved in hexanes one last time, and transferred to a tarred vial. The hexanes were 
then evaporated, leaving only 1-octanol in the vial, which was then weighed. 
 
Table 3. 1 Masses of the cartomizer cartridge after each burn 
Trial 
# 
Full 
Cartridge (g) 
After 1 
Burn (g) 
After 2 Burns 
(g) 
After 3 
Burns (g) 
1 6.5728 6.5251 6.4789 6.4323 
2 6.6337 6.5647 6.5156 6.4628 
3 6.6398 6.5840 6.5335 6.4726 
 
Table 3. 2 Changes in the mass of the cartomizer after each burn 
Trial # After 1 Burn (g) After 2 Burns (g) After 3 Burns (g) 
1 -0.0477 -0.0462 -0.0466 
2 -0.069 -0.0491 -0.0528 
3 -0.0558 -0.0505 -0.0609 
Standard 
Deviation 
0.0108 0.0022 0.0072 
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Table 3.2 shows the difference in the masses of the cartomizer (cartomizer 
masses shown in Table 3.1) after every burn. The changes in the masses of the 
cartomizer show that they decrease at a similar rate between burns.  
Table 3. 3 Amounts of 1-octanol isolated from three burns of a 5 M 1-octanol solution 
Trial # 
Flask 1 
(mg) 
Flask 2 
(mg) 
Standard Deviation 
(mg) 
1 29.7 7.6 15.6 
2 34.4 18.6 11.2 
3 30.3 2.8 19.4 
Table 3.3 shows how much 1-octanol was isolated in each flask after three 
burns. The collected results show that in each trial there was some disparity in the 
amount of 1-octanol present in each flask. The standard deviations range from 11.2 mg 
to 19.4 mg which is a large amount considering that in Flask 2 of Trial 3, only 2.8  mg 
of the 1-octanol was isolated. At this time the reason for the large deviation in the 
amounts is not understood, but several variables could be responsible, which include: 
the tightness of the seal at the mouth of the flask, whether or not there is equal flow of 
vapor into each flask, or the size of the collection flask employed. 
 
Table 3. 4 Retention of 1-octanol from vaporization to quantification of collected oil 
Trial 
# 
Solution 
Vaporized 
(mg) 
Expected 1-
Octanol (mg) 
Collected 1-Octanol 
(mg) 
Percent 
Retention 
1 140.5 111.0 37.3 33.6% 
2 170.9 135.0 53.0 39.3% 
3 167.2 132.1 33.1 25.1% 
 
The data in Table 3.4 shows the percent retention of 1-octanol from the three 
burns that were done during the quantification experiment. It was calculated that the 5M 
solution was 79% 1-octanol by volume. Adding up the values presented in Table 3.2 for 
each trial, 79% of the total sum was taken to determine the amount of 1-octanol that 
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was expected to be in the flasks. These values were compared to the total amounts of 1-
octanol collected in each trial (values in Table 3.3) to determine the percent of 1-octanol 
retained during the entire collection process. The data shows that the percent of 1-
octanol retained was low, ranging from 25-39%, but mostly consistent. It appears that 
the 1-octanol was either condensating on the tubing as the vapors were being pushed 
into the flask but not condensating on the sides of the flask, or only a small percentage 
of the 1-octanol was entering the gaseous state during each burn. This experiment 
should also be done with the other oils used in order to determine if low retention 
occurs as well. 
 
3.3 Methods 
3.3.1 Selection of Fungi and Volatile Oils 
In these experiments, several fungi were chosen to be used with the Fungal 
Smoker. These fungi were selected based on their ability to produce compounds as well 
as their immediate availability at the time of the project. The Dictionary of Natural 
Products, as well as the OU NPDG compound database were used to help decide which 
fungi to use. The first fungus, called Dubuque CZ-2 (Aspergillus terreus isolate SYW), 
was chosen because at that time isolation and elucidation work had just been finished on 
the fungus, and several compounds had been identified. The other three fungi that were 
tested in this project were chosen from a list of fungi that were readily available. The 
genus, as well as the species, of all of the fungi on the list were searched for on the 
Dictionary of Natural Products to determine the number of compounds  that had been 
isolated from each specific fungus. For the Fungal Smoker, fungi were chosen that 
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already had multiple, but not too many known compounds to simplify analysis. In a 
case with a large amount of known compounds, determination of new metabolites 
would be difficult, but with too few being produced, it could mean that the fungus is not 
capable of biosynthetically producing many metabolites. The Absidia genus was found 
to produce 5 known compounds, the Paraconiothrium genus produced 14 compounds 
with the brasiliense species producing 4 of those compounds, and the Beauveria genus 
was shown to produce 83 compounds with 43 of the compound being produced by the 
bassiana species. As a result of this search, the three fungi that were chosen for initial 
tests were TX0 0268 (Absidia sp. LF-W7), MD24 04 (Paraconiothyrium brasiliense), 
and NM6332  (Beauveria bassiana).  
Although there are many different volatile oils produced by soil microbes, six 
oils were chosen to be vaporized over the selected fungi to test this hypothesis. These 
studies have employed farnesol, 1-octen-3-ol, 1-octanol, 3-octanone, 3-methylbutanal, 
and heptanal. One of the reasons that these oils were chosen was due to the abundance 
of the oil produced by fungi, such as 1-octen-3-ol, which appeared in abundances 
ranging from 35-93% of all volatile compounds in several concentrated fungal 
distillates.
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 The other reason these oils were chosen was the bioactivities shown by 
these oils, such as quorum sensing induction, control of  growth and development, and 
alteration of stress resistance.
38-41
  
 
3.3.2 Experimental Protocol 
For the treatment of the fungi using the Fungal Smoker, three different 
concentrations of oils, a propylene glycol and glycerine control (1:1 mixture), as well as 
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a "no treatment control" were used. The concentrations used were molar values for each 
oil relative to the amount of the propylene glycol and glycerine solution. Since there 
was only room on the Fungal Smoker to use three concentrations, 0.5 and 1.0 M were 
selected to test the effects of exposure at relatively low concentrations, while 5.0 M was 
chosen as an extreme condition. With the Fungal Smoker having options to burn at 3, 8, 
or 24 hour intervals, an appropriate time setting had to be chosen for these experiments. 
The 3 hour setting was not chosen because too much moisture was produced by the 
vapors. The 8 hour setting significantly reduced this problem and allowed for more 
exposure to the volatile oils than the 24 hour setting would provide. As a result the 8 
hour setting was chosen. 
 Fungi were prepared in one liter Erlenmeyer flasks, on autoclaved cheerios and 
media. Ten flasks were prepared for each batch of experiments: two flasks were 
prepared for each of the three concentrations of oils tested, two flasks for the propylene 
glycol and glycerine control, and two flasks that did not receive any treatment. The 
fungi were allowed to grow in the flasks until a layer of fungus covered the tops of the 
cheerios. Most fungi took around one week to grow, with some growing faster than 
others. Once the fungus had covered the cheerios, the flasks were run on the Fungal 
Smoker for one week before being extracted with ethyl acetate. The resulting crude 
extracts were then analyzed using LCMS. The PDA chromatagrams of the extracts were 
compared to see if the there was a difference in the compounds produced between the 
control fungi and the fungi that received volatile oil treatments. 
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3.4 Fungal LCMS Results 
  
 With the Dubuque CZ-2 fungus, as shown in Figure 3.2, it appears that the 
production of two new metabolites was induced by the vaporization of the oils over the 
fungus. One new metabolite appears at around the 5.4 minute mark in the PDA 
chromatagram, while the other metabolite appears around the 6.8 minute mark. The m/z 
and UV maxima values for both compounds were compared to compounds known for 
Aspergillus terreus in the Dictionary of Natural Products. There were multiple 
compounds in the database that had similar m/z and UV values to the ones found for the 
newly produced metabolites, but none were found that completely matched what was 
shown in the LCMS data. It appears that these metabolites may be new compounds 
similar to some metabolites isolated from this genus.  
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Figure 3. 2 LCMS comparison of Dubuque CZ-2 fungal flasks 
 
 
 With the TX00268 TV8-2 fungus, in Figure 3.3, it appears that the different 
trials show the same compounds being produced. The only exceptions to this is that the 
5.0 M and the "No Treatment" are missing a peak at approximately 12.9 minutes, and 
the signals between 3 and 7 minutes are much weaker. There does not appear to be any 
reason to pursue further chemistry with this fungus. 
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Figure 3. 3 LCMS comparison of TX00268 TV8-2 fungal flask 
 
Looking at the LCMS comparison of the different concentrations for the 
MD2404 fungus, shown in Figure 3.4, there are some interesting results. In all of the 
treatments the compounds that are produced are the same outside of the 6.5 to 7.2 
minute range, albeit with different intensities. In the 5.0 M treatment, within the 6.5 to 
7.2 minute range there are three new compounds that are produced with a UV 
maximum of 241 nm, and the compounds have m/z values of 270, 272, and 320. These 
masses and UV value are similar to some brasilamide, pinthunamide, and 
isopimaradiene derivatives which have been previously isolated from this species of 
fungus. These induced metabolites may be new derivatives of these compounds.  
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Figure 3. 4 LCMS comparison of MD2404 fungal flasks 
 
 
 For the NM6332 fungus, the PDA chromatagrams, Figure 3.5, show some 
interesting results. Between the 10 and 15 minute marks, all of the treatments show the 
same compounds in present. Between the 3 to 7 minute marks, there appear to be 
several new compounds present in the 5.0 M treatment that do not show up in the 
chromatagrams for the other treatments. After comparing the UV data for each of the 
compounds to what was present in the Dictionary of Natural Products, there appear to 
be multiple known compounds that could be related to the ones that have been induced 
in the fungus. One compound in particular appears to be promising; the compound 
appears to have a molecular weight of 540 g/mole and has a UV maxima of 222 nm. 
These properties are similar to beauverolide B, which has a molecular weight of 543 
g/mole and a UV maximum of 222 nm.  
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Figure 3. 5 LCMS comparison of NM6332 fungal flasks 
 
 
3.5 Conclusions 
 In conclusion, a protocol was developed to vaporize volatile oils from soil 
microbes onto fungi at different concentrations. The troubleshooting of the equipment, 
time settings, selection of volatile oils, set up of flasks, age of fungi at the start of use, 
length of time that the vapors were delivered, and quantification of 1-octanol delivered 
were determined as part of the protocol. Four different fungi were also tested as part of 
the initial tests. At this time, standardization of the amount of oils delivered to the flasks 
still needs to be done, as well as the quantification of 1-octanol delivered at different 
concentrations. The quantification should also be done with the remaining oils as well. 
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Three of the four fungi initially tested showed promising results for the 
production of new metabolites. The LCMS data showed that the Dubuque CZ-2, 
MD2404, and NM6332 have potential for producing new metabolites when exposed to 
the oil vapors. The first thing that would need to be done with these fungi, would be to 
confirm that these compounds are really being produced from the Fungal Smoker 
treatment by rerunning the experiment with these fungi. Upon any confirmations, the 
fungi should be grown in a large scale, extracted, and the new compounds should be 
isolated and elucidated. Finally, fungi should continue to be screened using the Fungal 
Smoker for the ability to produce new compounds when exposed to the vapors 
produced by the volatile oils. If new compounds are truly being produced it would be of 
interest to determine which oils are resulting in the production of new compounds. 
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Chapter 4 
Development and Initial Testing of a Traumatic Injury Assay 
 
4.1 Introduction 
 Traumatic injury, especially injury to the brain, has become an important field of 
study. With new insights into impacts on the body and head, groups such as the 
National Football League (NFL) and the United States Department of Defense 
(USDOD) have become interested in protecting athletes and soldiers, respectively. 
Traumatic injury is defined as an injury resulting from kinetic energy applied to a nerve 
or limb and can cause a range of physiological effects.
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As of 2011, it is believed that 
the number of service-men who suffered blast-related traumatic brain injuries is as high 
as 320,000 from the wars in Iraq and Afghanistan alone.
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 Many of the traumatic 
injuries in soldiers occur as a result of the shockwaves from blasts. These shockwaves 
can transfer kinetic energy to the central nervous system, causing lung injury and 
hemorrhage leading to hypoxia and ischemia, as well as blast-induced neurotrauma.
44
     
Symptoms from trauma have also been investigated in NFL athletes. In a study of 
retired NFL football players between the ages of 30 and 49, it was found that they were 
being diagnosed with dementia 20 times the rate of the age-matched population.
45
 It was 
also found that there was decreased cerebral perfusion, higher incidences of depression, 
obesity, as well as attentional and memory problems in the retired NFL players 
compared to the general population .
45
As a result of these types of serious symptoms 
associated with traumatic injuries, it is crucial to conduct research in order to discover  
new treatments and drugs that can prevent or repair damage done by these injuries. 
48 
 With all of the new data that has surfaced pertaining to the effects of traumatic 
injuries, there are increased efforts to find new ways to try to prevent or repair damage 
on the body and head from these types of injuries. At this time, no viable treatment has 
been discovered, but multiple groups have begun to explore various aspects related to 
traumatic injury. Some of the approaches include targeting specific proteins and 
studying their physiological effects, as well as using higher level organisms, like mice, 
to understand the mechanisms of traumatic injuries. Only a few research groups are 
currently investigating the problem using lower level organisms, including, but not 
limited to, fruit flies, nematodes, and brine shrimp. The use of these types of organisms 
not only allow for lower costs and larger sample sizes in studying physiological effects, 
but also does not require extra approval from the government. Unfortunately, the results 
obtained in studying these organisms do not always transfer over to the higher level 
organisms. The Wassarman group is one of the groups that has been using lower level 
organisms for traumatic injury research. This research group has been using fruit flies to 
study the physiological and neurological effects of the injuries, as well as testing several 
compounds for the improvement of longetivity in injured flies.
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 To test the 
aforementioned aspects of traumatic injury, the Wassarman group developed an assay 
that would consistently inflict traumatic injury to the fruit flies using a fly culture tube 
connected to a spring, which is pulled back to a set angle and released to impact a 
surface.
48
 These studies looked at the survival of the flies at different ages, with 
different amounts of impacts, effects of gender, effects of different fly strains, and 
treatments with several compounds. 
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 In this project, the goal was to develop an assay where traumatic injury can be 
induced into lower level organisms. Once injured, the organism would be treated with 
pure compounds and fungal extracts in order to screen for activity in preventing or 
repairing the traumatic injury. The development of the project focuses on the selection 
of an organism, developing a protocol for inducing the injury, troubleshooting problems 
with the method, and obtaining initial results from the pure compounds and fungal 
extracts. 
 
4.2 Development of Protocol 
4.2.1  Cannon and Projectiles 
 The cannon, shown in Figure 4.1, was set up so that the missiles angle of impact 
with the target was roughly between 77.5 and 85 degrees, resulting in an angle of 
reflection of 10 to 25 degrees. The  target wall was positioned 7.5 feet away from the 
cannon. Once aimed, the cannon was loaded by pushing the projectile into the back of 
the barrel. At this point an external air pump was used to compress air into the holding 
area. A pressure gauge informed the operator of the air pressure in the cannon and was 
used between the lower and upper limits of 15 and 65 pounds per square inch (psi) 
respectively. When the operator had gone through the pre-firing checklist, the trigger 
was pulled, which released the air out of the holding area, into the barrel and the 
projectile was ejected at the target wall. Any residual air in the cannon was released 
through another pull on the trigger which allowed the cannon to be loaded again 
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Target 
Barrel 
Air  
Reservoir 
Pressure 
Gauge 
Trigger 
Figure 4. 1 Labeled diagram of the traumatic injury inducing cannon 
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4.2.2 Test Subjects 
 Once the protocol for using the cannon was developed, the next step was to 
figure out what kind of projectile would be used to deliver the traumatic injury, as well 
as to determine how to set up the vessels containing the test subjects. Microcentrifuge 
tubes, with a 1.5 mL volume, were chosen as the vessel for the test subjects due to them 
being small enough to fit multiple tubes into a projectile, their low cost, and their ability 
to hold organisms and liquids sealed within the tube. While doing the initial shots out of 
the cannon, it was realized that the Microcentrifuge tubes had a problem in that they 
would shatter upon impact; as a result multiple methods were tested to reduce the stress 
on the tubes to prevent them from shattering. At first different grains were used with 
minimal success; afterwards it was found that making a coozy with slots for the 
microcentrifuge tubes reduced stress on the tubes enough where they were able to 
withstand shots even at 65 psi, the highest pressure tested. Figure 4.2A shows how the 
microcentrifuge tubes (shown in red) fit into the foam coozy. The microcentrifuges and 
the coozy are slid into the projectile so that the caps of the tubes are facing the closed 
end of the projectile (the impact side). 
 Four different designs for the projectile were tested during the initial 
development of the procedure. The designs for projectiles 1 through 4 are shown in 
Figure 4.2B and each of them had its individual positive and negative qualities. With 
Projectile 1, the length was ideal for shooting three instead of two microcentrifuge tubes 
resulting in less shots required, also the metal top helped strengthen the missile. The 
problem with 1 was that the metal top increased the mass of the missile giving it more 
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momentum and with the top having a smaller surface area, the amount of damage to the 
target upon impact was increased. Projectile 2 can hold 3 microcentrifuge tubes as well 
but has a flat, more spread impact surface, reducing the damage done to the target; 
without the metal top, 2 is a bit weaker than 1. Projectile 3 is probably the cheapest to 
make out of the four projectiles, but only two tubes can be fired at a time. Projectile 4 
had by far the largest mass out of the four projectiles and the highest cost, and was only 
capable of holding two microcentrifuge tubes. 4 was also not capable of reaching the 
target completely and would damage the base of the target, but the design was the most 
sturdy out of all of the missiles. 
Figure 4. 2 A) Set up of brine shrimp traumatization projectile B) Different projectile 
designs tested 
 
 
4.2.2 Test Subjects 
 One of the first steps in designing the project was to determine the type of 
organism to use. The overall goal was to find an organism where multiple test subjects 
could be tested at the same time, with 40-60% of the subjects surviving the impact 48 
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hours after firing. Moreover, the organism needed to be hardy enough to withstand an 
impact at a certain pressure, but not too hardy to require an impact beyond the pressure 
capabilities of the cannon. Multiple organisms were tested for these characteristics, 
including wax worms, meal worms, crickets, fruit flies, nematodes, and brine shrimp. 
Wax worms were the worst test specimen for this study because even under the 
lowest cannon pressure, the wax worms disintegrated. Meal worms mostly survived 
intact at low pressures, but after the impact they would die within 24 hours. Fruit flies 
were tested and a good percentage of the flies were able to survive. Although fruit flies 
survived the impact, they posed several problems. First, the fruit flies needed to be fed 
in order to keep them alive for multiple days, leading to more variables that would need 
to be controlled. Also, there was no reliable method to treat the flies with consistent 
amounts of the test materials. Finally, the reproductive speed of the flies also provided a 
problem since transfers would need to be performed to prevent inaccurate counts 
resulting from new fruit flies hatching. The next organism, crickets, were able to 
survive higher impacts than the rest of the organisms,however,the crickets posed 
problems due to difficulties in treating them with the test samples, and only one cricket 
could be fired at a time. Although crickets may not be a good option for initial 
screening, they could provide opportunities for higher level screenings. 
In the end, two organisms, brine shrimp (Artemia salina) and nematodes 
(Caenorhabditis elegans), were determined to have the best potential for test specimens 
in this study. Since precedence exists for using both brine shrimp and nematodes in 
assays, growth protocols have been developed for both organisms. The maturation of 
brine shrimp and nematodes is relatively short and they are small enough where 
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multiple subjects can be tested with each shot. Also, the treatment of both organisms 
with the test sample is as simple as injecting the materials into the solution with the test 
subjects. Although both organisms showed good potential for this project, brine shrimp 
were selected for initial work due to limited time allowed for developing the project, 
and the shrimp having fewer variables to account for. Even so, nematodes appear to be 
a better model for the project since more information pertaining to this organism is 
readily available and there are various mutants that can be applied to test a range of 
different variables. They show potential for future work but there are still many 
variables that need to be tested before a set protocol can be prepared for using the 
organism.  
 
4.3 Troubleshooting Brine Shrimp 
 In the initial studies, samples treated with glucosamine showed activity in 
decreasing the fatal damage to the brine shrimp, represented by an increased survival 
percentage. Once the activity was confirmed, a concentration study was performed. The 
results of this study showed that there was no activity from glucosamine increasing the 
survival of brine shrimp. The study was then repeated and the results showed irregular 
data where certain samples showed activity while others showed none. At this point, the 
experimental design was adjusted in order to try to repeat the initial results. 
 The first test was related to the hatching conditions of the brine shrimp. Initially 
the brine shrimp were grown in a 500 mL Erlenmeyer flask with 300 mL of distilled 
water and Instant Ocean salt mixture at room temperature (~22°C). A Pasteur pipette 
was used to bubble house air into the growth flask to keep the solution aerated. This 
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method required a 72 hour grow up and resulted with inconsistent yields of shrimp. The 
next test incorporated an intermediate flask that bubbled the house air through water 
before passing the air into the brine shrimp growth flask. This was done in order to 
remove any impurities that may have existed in the house air. This method did not 
improve the consistency of brine shrimp hatching. After the test failed, it was believed 
that the batch of brine shrimp eggs was compromised. Although a different batch of 
eggs was tested, there was no improvement. Finally, in the literature, a method was 
found that used an orbital shaker to hatch brine shrimp.
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 The flask with the brine 
shrimp eggs was placed into a New Brunswick Scientific, Innova
®
44 orbital shaker set 
at 28°C and 130 rpm as shown in Figure 4.3. After 48 hours there was an increased 
amount of hatched brine shrimp in the flask, which matched what was commonly 
shown in the literature. It should be noted that this method was consistently repeated in 
this project to hatch shrimp. 
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Figure 4. 3 A) Brine shrimp hatching flask on orbital shaker B) Orbital shaker with the 
hatchery 
 
 
 With the brine shrimp still not showing consistent results after impact, the 
procedure with the cannon was standardized. Several variables were analyzed related to 
the cannon including the average speed and standard deviation of the missiles, angle of 
impact on the target, and distance of the cannon from the target. To determine the initial 
velocity of the missiles, two photogates were employed to find the amount of time it 
took the missile to travel a set distance. Using Equation 1, where D represents distance 
and T represents time, the velocity and the standard deviation were calculated. This 
ensured the inconsistencies with firing of the cannon were not the source of the 
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problems for the results. Next, the cannon was set to fire at a distance of 7.5 ft with an 
angle of impact of 77.5-85° to the target to ensure the impacts would be consistent. At 
this point the brine shrimp were tested with a glucosamine treatment one last time. Once 
again, the experimental results showed that the glucosamine was inactive and 
glucosamine was dropped as a hit in the assay. 
Equation 1: Calculation to determine velocity of the missile 
𝑽 =
𝑫
𝑻
 
 
4.4 Cannon Velocity Studies 
 To determine whether the cannon was firing at a consistent velocity, an 
investigation into the velocity the projectiles were being launched at was conducted. In 
order to carry out this type of investigation, it was necessary to obtain two photogates 
attached to a timing mechanism. The elapsed time to travel a set distance was 
determined from the photogates by starting the timer when the infrared plane was 
broken at the first photogate and stopping the timer when the plane was broken on the 
second one. Using the time and the set distance between the two photogates, the 
velocity of the missile exiting the barrel was determined. 
 The photogates were connected to the timer and placed on a clipboard allowing 
for easy loading of the cannon while maintaining the same distance between the 
photogates. At this point, the outer and inner diameters between the two photogates 
were measured using calipers. The average of the diameters was used as the value for 
the travel distance of the projectile. The photogates were then placed in front of the 
cannon barrel, before ensuring they were perfectly aligned to prevent the projectile from 
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hitting either one. At this point, the cannon was pressurized and fired. The 
measurements were done in triplicate at 15, 25, 35, 45, 55, and 65 psi. The results are 
shown in Table 4.1 and Figure 4.4. 
Table 4. 1 Average velocities over a range of launch pressures 
Pressure 
(psi) 
Average Velocity 
(mph) 
Standard Deviation 
(mph) 
15 38.53 0.50 
25 60.96 0.73 
35 74.19 1.86 
45 85.59 1.44 
55 93.71 3.42 
65 101.30 1.60 
 
Figure 4. 4 Graph of the average velocity of the projectile using different launch 
pressure 
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4.5 Initial Assay Results 
4.5.1 Pure Compound Results 
Figure 4. 5 Pre-treatment assay results using select pure compounds 
 
Figure 4. 6 Post-treatment assay results using select pure compounds 
 
 
From the compounds that were tested for activity in preventing damage from 
traumatic injury, muramic acid appeared to initially show activity at a concentration of 
50 μM. As observed from Figure 4.5, approximately 70% of brine shrimp survived from 
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the initial test. When muramic acid was retested, activity was weaker, with about 55% 
of the brine shrimp surviving. ISRIB also showed slight activity at 25μM with 
approximately 55% of brine shrimp surviving. When the compounds were tested for 
activity in repairing damage from traumatic injury, it is observed from Figure 4.6 that 
none of the compounds showed exceptional activity. 
 
4.5.2 Plate 141 Extract Results 
Figure 4. 7 First part of the pre-treatment assay results using fungal extracts 
 
Figure 4. 8 Second part of the pre-treatment assay results using fungal extracts 
 
Figure 4. 9 First part of the post-treatment assay results using fungal extracts 
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Figure 4. 10 Second part of the post-treatment assay results using fungal extracts 
 
 
 When the fungal extracts were tested for activity in preventing damage from 
traumatic injury, Figures 4.7 and 4.8 show there was no extract that increased the 
survival rate in brine shrimp. When the extracts were tested to determine if they 
repaired damage from traumatic injury, Figure 4.9 shows no extracts that increased 
survival for the brine shrimp, but from Figure 4.10, it is observed that wells D7 and G7 
had about 60 and 55% survival respectively in brine shrimp. Wells D7 and G7 represent 
a slight increase in survival compared to the negative control for the post-treated 
shrimp. 
 
4.5.3 Summary of Results 
 From the 12 pure compounds that were tested, it appears that muramic acid 
shows the most promise, while ISRIB shows some promise as well for preventing 
damage from traumatic injury. Several compounds did not show any activity in 
preventing or repairing damage while the remaining ones appeared to actually do more 
harm than good in regards to the survival rate of the shrimp. 
 Out of the 40 fungal extracts that were tested, a couple of the extracts appeared 
to do more harm than good with the brine shrimp while the majority showed no activity 
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in preventing or repairing damage from traumatic injury. Although only the extracts in 
wells D7 and G7 showed potential to repair damage and increased the survival of the 
shrimp, a confirmation would need to be done first before further investigation into the 
active compounds would be done. 
 
4.6 Future Directions 
There are several directions in which this project can progress. First, more 
extract plates can be tested for activity, as there is only a small possibility that the 
extracts tested from only one 96-well plate would provide any active materials. A 
minimum of 100 extracts should be screened for this project, since screening more 
plates should increase the probability of finding an extract that exhibits preventative or 
reparative activities against traumatic injury. Also, with the brine shrimp, explorations 
in the effects of the extracts at a slightly lower launch pressure can be done by going 
from 20 psi to 15 psi. Lowering the pressure may help this project, considering that a 
higher pressure may lead to false negatives. Moreover, it is possible that the pure 
compounds are being tested at concentrations that are too high in this project, and it 
may be of value to retest them all at lower concentrations. Further improvement directly 
related to this project would be to conduct additional testing with muramic acid, which 
in the current studies has shown activity. 
Another potential avenue for the project would be to develop a protocol to use 
nematodes with the cannon. There are two main variables required before the 
nematodes could be used for screening. The first variable is the optimal age of the 
nematodes after synchronization. An ideal age would be when the nematodes have high 
63 
movement and liveliness and are hardy enough not to fragment upon impact. The 
second variable is the number of times that the nematodes would need to be fired at 65 
psi to induce a traumatic injury. These two variables appear to be the last two pieces 
that need to be determined before nematodes can be used to test extracts and 
compounds. 
 
4.7 Conclusions 
 Along with nematodes, brine shrimp were chosen as the best organisms for this 
assay. At this point a set protocol has been determined for the use of brine shrimp. With 
initial testing, most of the materials showed no activity in preventing or repairing 
damage done from the traumatic injuries in the brine shrimp. It appears that muramic 
acid as well as the fungal extracts in wells D7 and G7 (to a lesser degree) from plate 
141 showed activity in preventing and repairing damage, respectively. Additional 
investigations should be conducted to confirm these activities and to observe activities 
at different concentrations. Finalizing a protocol for nematodes would also be of value 
at this point in the experiment. 
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Appendix 
 
A.1 NMR spectra for Dinapinone AB1/2 
a) 
1
H NMR (400MHz) in CDCl3 
 
b)
13
C NMR (400MHz) in CDCl3 
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c) HSQC NMR (400MHz) in CDCl3 
 
d) COSY NMR (400MHz) in CDCl3 
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e) HMBC NMR (400MHz) in CDCl3 
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A.2 HRESIMS for Dinapinone A1/2 
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A.3 
1
H NMR (400MHz) in CDCl2 for Dinapinone A2 
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A.4 
1
H NMR Table for 3 and 5 and 
13
C NMR Table for 3 
1
H data for 3 and 5 
3 5 
No. δH
a,b,c Splitting J (Hz) No. δH
a,b,c Splitting J (Hz) 
1 1.3 M   1 0.89 t 6.49, 6.49 
2 6.96 S   2 1.3 m 
 
3 9.67 S   3 1.46 m 
 
4 1.62 ddd   4 1.6 ddd 11.33, 20.79 
5 0.9 T 3.21 5 1.68 ddd 
 
6 1.89 ddd   6 1.89 ddd 
 
7 1.34 M   7 2.11 ddd 13.13, 19.87 
8 1.52 M   8 3.09 dd 14.23, 14.23 
9 2.09 ddd 7.59, 15.48 9 3.83 s 
 
10 1.67 ddd   10 3.94 m 
 
11 3.84 S   11 4.19 dddd 
 
12 3.92 M   12 4.86 dddd 
 
13 4.2 dddd   13 6.69 s 
 
14 4.87 dddd   14 6.95 s 
 
15 6.7 S   15 9.66 s 
 
16 13.7 S   16 13.72 s 
 
17 3.1 dd   
    18 1.32 M   
    a Measured in CDCl3 
b Measured on 400MHz instrument c δ in ppm 
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13
C data for 3 
3 
No. δa,b,c No. δa,b,c 
1 14.0 24 98.11 
2 14.01 25 98.1 
3 22.58 26 99.3 
4 22.6 27 99.34 
5 24.93 28 108.14 
6 25.12 29 108.4 
7 31.73 30 108.43 
8 31.74 31 116.23 
9 32.84 32 116.26 
10 32.98 33 132.65 
11 37.76 34 132.7 
12 38.4 35 140.07 
13 41.83 36 140.08 
14 42.13 37 155.35 
15 42.2 38 155.4 
16 42.91 39 161.4u u6 
17 55.95 40 161.5 
18 56.0 41 162.83 
19 69.02 42 162.87 
20 69.53 43 171.22 
21 73.36 44 171.26 
22 78.13 45 
 
23 78.76 46 
 a Measured in CDCl3 
b Measured on 400MHz instrument 
c δ in ppm 
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A.5 
1
H NMR (400 MHz) in CDCl3 for the isolated xanthoquinodin 
 
A.6 
1
H NMR table for the isolated xanthoquinodin 
Xanthoquinodin (6) 
No. δH
a,b,c Splitting J (Hz) 
1 1.57 s 
 
2 1.93 m 
 
3 2.39 dd 6.62, 19.66 
4 2.45 s 
 
5 2.55 s 
 
6 2.89 d 17.82 
7 2.98 dd 17.82, 64.91 
8 3.06 d 17.81 
9 3.7 s 
 
10 4.27 dd 
 
11 4.8 dd 6.19 
12 6.08 s 
 
13 6.48 dd 
 
14 6.68 dd 7.68 
15 7.08 s 
 
16 7.57 s 
 
17 11.71 s 
 
18 11.96 s 
 
19 13.94 s   
a Measured in CDCl3, 
b Measured on 400MHz instrument 
c δ in ppm 
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A.7 NMR and IR Spectra for Microsphaerin D 
a) 
1
H NMR (400MHz) in CD3OD 
 
b) 
1
H NMR (400MHz) in acetone-d6 
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c) 
13
C NMR (400MHz) in acetone-d6 
 
d) HSQC NMR (500MHz) in acetone-d6 
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e) COSY NMR (500MHz) in acetone-d6 
 
f) HMBC NMR (500MHz) in acetone-d6 
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g) FTIR spectrum 
 
 
A.8 
1
H NMR table for microsphaerin D   
Microsphaerin D 
No. δH
a,b,c Splitting 
1 1.75 s 
2 1.96 s 
3 2.21 s 
4 2.25 s 
5 2.48 dd 
6 2.66 d 
7 3.86 s 
8 6.14 s 
9 6.14 s 
10 6.22 s 
11 6.26 s 
a measured in CD3OD 
b measured on 400MHz 
Instrument c δ in ppm, J in Hz 
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A.9 NMR Spectra for the unidentified structure 
a) 
1
H NMR (400MHz) in CDCl3 
 
b) 
13
C NMR (400MHz) in CDCl3 
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c) HSQC NMR (400MHz) in CDCl3 
 
d) COSY NMR (400MHz) in CDCl3 
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e) HMBC NMR (400MHz) in CDCl3
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A.10 Trichomonas Assay results for the dinapinones
a 
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a 
All assays done by Jarrod King (University of Oklahoma) 
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A.11 Trichomonas assay results for the Xanthoquinodins
a 
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JK-164D
Xanthoquinodin
2 Day Exposure
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a 
All assays done by Jarrod King (University of Oklahoma) 
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A.12 Trichomonas assay results for dinapinones and xanthoquinodins in an 
anaerobic chamber
a
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a 
All assays done by Jarrod King (University of Oklahoma) 
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A.13 Trichomonas assay results for microsphaerin D and the unidentified 
compound
a
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a 
All assays done by Jarrod King (University of Oklahoma) 
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A.14 TI values from the trichomonas assay for all of the identified compounds 
a 
 
Compound TI value Project 
Dinapinone A2 3 Wailua PDA-3 Contaminant 
Dinapinone AB1/AB2 5 Wailua PDA-3 Contaminant 
42C 12.5 Wailua PDA-3 Contaminant 
42C (anaerobic) 0 Wailua PDA-3 Contaminant 
Xanthoquinodin 5 Tracy MEA-2 
Microsphaerin D 0.3 Boars Tusk PFA-1 
 
a 
All assays done by Jarrod King (University of Oklahoma) 
 
 
